Aviragen Therapeutics (AVIR) is Initiated by H.C. Wainwright to Buy, Price Target at $5

Aviragen Therapeutics (AVIR) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $5. H.C. Wainwright advised their investors in a research report released on Jul 13, 2016.

Aviragen Therapeutics

Leave a Reply

Aviragen Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Aviragen Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.